Targeting clock genes offers new avenues for cancer treatment, and various targets (e.g., CLK8 [290], mTOR [291]) and drugs (e.g., MLN4924 [292]) are under development with ongoing clinical trials. This evidence concerns the gene MTOR and cancer.